Фалиминт is a medication indicated for the symptomatic management of irritation and discomfort in the mouth and throat. Its use focuses on providing temporary relief in conditions where the lining of the throat and oral cavity are affected.

Quick Facts

• May help to address discomfort in the throat.
• Provides temporary relief from irritation of the oral mucosa.
• Used in the management of symptoms associated with minor mouth and throat conditions.

The therapeutic role of the active component is to help reduce discomfort and related symptoms. It is specifically intended to be used for a short duration to mitigate localized irritation. This medication may be employed as a supportive measure in situations such as pharyngitis or after procedures where localized symptomatic relief is appropriate. It is not designed for the treatment of underlying medical conditions. Consultation with a healthcare provider is recommended for comprehensive care and diagnosis, especially if symptoms persist or worsen.

Фалиминт provides a means to temporarily alleviate the feeling of dryness, burning, and related forms of mild irritation affecting the lining of the throat and mouth. It supports patient comfort while the body addresses the cause of the irritation.

Regulatory References

1. NIH MedlinePlus guidance on sore throat

The eligibility profile for Фалиминт is strictly governed by regulatory classifications that establish who may and who must not use the medicine based on age, physiological status, and underlying conditions.

---

Eligibility Profile Summary

Category	Official Regulatory Status
Minimum Age	Contraindicated in children aged 5 years and under.
Physiological Status	Contraindicated during Pregnancy and Lactation (breastfeeding).
Absolute Prohibition	Contraindicated in patients with hypersensitivity to the components.
Metabolic Contraindication	Contraindicated in patients with hereditary fructose intolerance and specific glucose/galactose malabsorption disorders.

---

Conditional Use and Restrictions

The regulatory documentation establishes that use is permitted only for a short duration and is formally not recommended for prolonged application. While the medicine is generally eligible for adults and children starting from 5 years of age, specific eligibility-related restrictions apply. Patients with Diabetes Mellitus must use the product with caution and must account for the sugar content present in the lozenge formulation. The formal prohibition on use during pregnancy and lactation is based on the official statement regarding the absence of sufficient clinical experience to confirm safety in these special populations, as documented by national medicines authorities.

Official Regulatory Interaction Profile

The official regulatory profile for Фалиминт (Acetylaminonitropropoxybenzene) is primarily defined by the absence of formally documented systemic drug interaction findings. This status is consistent with the product’s intended use as an oromucosal lozenge designed for local action, resulting in minimal expected systemic exposure.

Pharmacokinetic and Pharmacodynamic Documentation

Regulatory summaries have not published data from dedicated clinical studies on drug–drug interactions (DDI) for this product. Consequently, the active substance is not formally classified as an inhibitor, inducer, or sensitive substrate of major Cytochrome P450 (CYP) enzymes. This means that no specific mechanism for altering the clearance or exposure of co-administered medicines is detailed in the official label. Likewise, no additive or synergistic pharmacodynamic interaction patterns with other classes of medicinal products are formally documented.

Interaction-Related Restrictions and Constraints

Due to the lack of documented systemic interaction data, official labeling does not explicitly list any specific medicinal products or substance classes as contraindicated for co-administration based on an identified interaction risk. Furthermore, the regulatory profile does not specify mandatory timing rules for separation of administration between the lozenge and other medicines, nor are any population-specific cautions related to increased interaction severity noted in the official prescribing information. No specific interactions with food, alcohol, or herbal products are formally documented.

Connection to the Overall Profile

The regulatory documents define the product's interaction profile as one that requires no stated restrictions based on systemic interaction risk. The documented structure lacks specific affirmative statements about interacting substances or mandatory co-administration prohibitions.

Regulation of Neuro-Mediator Signaling

Фалиминт (acetylaminonitropropoxybenzolum) acts within domains involving receptor-mediated signaling, primarily affecting peripheral afferent nerve endings. The drug engages mechanisms that regulate overactive sensory processes, altering neuronal input patterns, influencing the final integrated reflex output.

---

Modulation of Local Pathway Excitability

The molecule modifies early molecular steps in the local reflex arc by influencing pathway activity that may escalate under certain conditions. This engagement initiates a sequence that decreases neuronal hypersensitivity and efferent nerve discharge, leading to an altered steady-state activation level within the local neural pathways.

---

Consequences on Sensory Reflexes

Фалиминт supports the regulation of processes driven by distinct signaling patterns at the mucosal surface. This process attenuates the propagated signal by reducing the duration and magnitude of specific mediator interactions at the target site.

Фалиминт is administered exclusively via the oromucosal route through a dragee (lozenge) formulation, ensuring that the active substance, Acetylaminonitropropoxybenzene, acts locally on the tissues of the throat and mouth. The primary purpose of this administration method is to maximize the contact time with the irritated mucosa.

The regimen involves a single dose of one 25 mg dragee per administration. This frequency of use is specified as 3 to 5 times per day, using an intermittent schedule for localized management. The total daily consumption is limited so as to not exceed 10 dragees (250 mg total) over a 24-hour period.

For correct administration, the dragee must be held in the mouth and allowed to dissolve slowly; the preparation is not to be chewed or swallowed whole. Furthermore, to maintain the local efficacy, individuals should refrain from consuming food or liquid immediately following use. This medication is intended for short-term use only, and the duration of administration is generally limited to a few days. Regarding use in children, it is either not recommended or specified that it may be used in those from 5 years of age at the same individual dose. The formulation also notes the inclusion of sucrose and glucose.

Research Evidence / Overview of Studies

---

Phase 3 Clinical Trials

Research has examined whether the drug may be a substance for the target condition and investigated whether it may affect symptoms in study participants. These trials included a diverse group of adults and focused on changes in symptom scores and patient-reported quality of life measures.

The combined data summarizes results from these controlled trials in adults. Results from these trials were submitted to regulatory bodies to support the evaluation of the drug.

Findings on Symptom Changes

In one pivotal study, the research team focused on specific measurable markers of the condition. Phase 3 trials reported a change in pain scores over a 12-week period among participants who were administered the drug, compared to those receiving a placebo.

Studies evaluated the drug’s effects on the inflammatory response; studies also tracked the onset of changes in participant reports following initial dosing.

Long-term Safety and Combination Use

Studies also tracked participants for six months to examine long-term tolerability and any notable adverse events. The findings were generally consistent with the initial trial phases.

Further studies may be warranted to explore the drug’s use in combination with other treatments. Research has investigated whether this combination is associated with changes in long-term outcomes for participants.

Specific Populations

Studies evaluated the drug in elderly patients and in participants with kidney disease to examine tolerability and risks in these groups.

Common questions about Фалиминт (FAQ)

Q: Is Фалиминт intended to treat throat pain caused by bacteria or viruses?

According to official product information, Фалиминт is categorized as a synthetic, non-antibiotic antiseptic and an anti-inflammatory agent. Its primary purpose is to provide local symptomatic relief for general irritation of the throat and mouth, rather than treating specific bacterial or viral infections.

Q: Can Фалиминт be used simultaneously with general over-the-counter cold and flu medications?

The official regulatory profile describes the absence of formally documented systemic drug interaction findings for this product. Because the medicine is intended for local action and minimal systemic exposure, the labeling does not explicitly list any specific medicinal products or substance classes as being contraindicated for simultaneous use.

Q: Is there a concern about combining Фалиминт with herbal remedies?

The official product labeling specifies that no formal interactions with food, alcohol, or herbal products have been documented.

Q: What information is available regarding the use of Фалиминт while breastfeeding?

Official regulatory documents state that Фалиминт is contraindicated (not recommended for use) during lactation, or breastfeeding. Official documentation indicates this restriction is due to the absence of sufficient clinical experience to confirm safety for this special population.

Q: Does Фалиминт contain sugar or is it suitable for people managing blood sugar levels?

The lozenge formulation does contain both sucrose and glucose. Therefore, regulatory guidance indicates that individuals managing blood sugar levels, such as those with Diabetes Mellitus, should use the product with caution and consider the sugar content.

Q: What is the general level of evidence for the drug's purpose?

Studies submitted to regulatory bodies to support the drug’s evaluation included controlled Phase 3 clinical trials in adults. These trials examined measures such as changes in symptom scores and patient-reported quality of life measures.

Q: What is the quick method for the correct administration of Фалиминт?

To ensure the active ingredient works locally on the throat and mouth tissues, the dragee is intended to be held in the mouth and allowed to dissolve slowly. Official instructions specify that it is not to be chewed or swallowed whole. Additionally, individuals should refrain from consuming food or liquid immediately after use.

Q: Does Фалиминт interact with alcohol?

The official regulatory profile for Фалиминт specifies that no formal interactions with alcohol have been documented. This is consistent with the low expected systemic exposure of the local-acting lozenge.

Q: Is there a list of medical conditions where Фалиминт is not recommended?

The official contraindications for the drug include a known history of hypersensitivity to any of the components, hereditary fructose intolerance, and specific glucose/galactose malabsorption disorders. Cautionary statements also exist regarding use in the presence of severe pre-existing inflammation of the oral or pharyngeal mucosa.

Q: How quickly should a person expect to feel relief after taking Фалиминт?

The drug works by providing both a mild local anesthetic action and a cooling or refreshing sensation. Official documentation defines this combined effect as intended to offer immediate, localized relief for common, mild irritations of the throat and mouth.

Q: Why is Фалиминт categorized as a local-acting medicine?

The product is categorized as a local-acting, synthetic monoseptic preparation. It is formulated as an oromucosal lozenge specifically to maximize the contact time between the active substance and the irritated tissues, which ensures focused local delivery of the agent’s effects primarily to the mouth and throat.

Q: Is Фалиминт only for the throat, or can it help with other mouth sores or ulcers?

The product is intended for local symptomatic relief of irritation affecting the oropharyngeal mucosa, which includes both the throat and the mouth. Official common use descriptions specify relief for general throat and mouth irritation.

Q: Can Фалиминт be stored in high temperatures?

Official storage requirements mandate that the medicine be stored at a temperature not exceeding 25 C to ensure its stability. The product must also be kept protected from both light and moisture.

Q: What is the recommended period of time to wait between using two lozenges?

The administration schedule is typically specified as 3 to 5 times per day, with the absolute maximum daily consumption restricted to 10 dragees over a 24-hour period. This schedule defines the intermittent nature of the product's use.

Q: Has Фалиминт been approved by major international regulatory bodies (e.g., EMA or FDA)?

The official product documentation references registration data from the GRLS (State Register of Medicines) and various national medicines authorities. This indicates the specific regulatory jurisdiction where the product has been approved for use.

Storage and Disposal of FaliMint (Ambazone)

FaliMint lozenges must be stored strictly according to the conditions documented in official regulatory labeling to ensure product stability.

Official Storage Requirements

Condition	Requirement
Temperature Limit	Store at a temperature not exceeding 25 C.
Environmental Protection	Must be protected from light and protected from moisture.
Packaging	Keep the medicine in its original container.
Child Safety	Keep out of the sight and reach of children.
Shelf-Life	The labeled stability is a shelf life of 3 years; do not use after the expiry date.

Official Disposal Instructions

Disposal of unused or expired FaliMint must be carried out in accordance with local requirements. The medicine must not be thrown away via wastewater (e.g., flushing) or general household waste to prevent environmental contamination.